Sugi Predict

Sugi Predict / Compounds / SCHEMBL400143

SCHEMBL400143

SCHEMBL400143

Cc1ncc(C(=O)O)c(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 9/20 0.60
▸ LDHA P00338 1/20 0.53
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ ALDH1A1 P00352 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ NTRK3 Q16288 3/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HSD11B1 P28845 1/20 0.50
▸ NTRK2 Q16620 1/20 0.47
▸ HPGD P15428 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971175 0.88 SMN1; SMN2 (0.49) NTRK1LDHAKMT2AMAPTALDH1A1
SCHEMBL16220580 0.88 NTRK1 (0.59) NTRK1MEN1KMT2AMAPTALDH1A1
SCHEMBL1967935 0.86 MEN1 (0.50) NTRK1LDHAMEN1KMT2AALDH1A1
SCHEMBL6488782 0.85 NPC1 (0.49) NTRK1MEN1KMT2AMAPTALDH1A1
SCHEMBL1969442 0.85 NTRK1 (0.46) NTRK1MEN1KMT2AMAPTALDH1A1
SCHEMBL12868320 0.84 NTRK1 (0.55) NTRK1LDHAMEN1KMT2AMAPT
SCHEMBL1015675 0.84 NTRK1 (0.58) NTRK1MEN1KMT2AMAPTALDH1A1
SCHEMBL1971235 0.84 KMO (0.47) NTRK1LDHA
SCHEMBL1969326 0.84 DHODH (0.51) NTRK1LDHAMEN1KMT2AMAPT
SCHEMBL6491306 0.82 PTPN1 (0.46) NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118344873-A Silicon nitride etching solution for inhibiting tip oxide regeneration, preparation method and application 浙江奥首材料科技有限公司 2024-07-16 — — CN claimed
CN-101563328-B substituted heteroaryl Pyridopyrimidinone derivatives SANOFI AVENTIS 2012-03-14 — — CN claimed
CN-102164896-A Phenethylamide derivatives and their heterocyclic analogues ACTELION PHARMACEUTICALS LTD 2011-08-24 — — CN claimed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 — — WO claimed
EP-2121635-A2 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-25 — — EP claimed
CN-101563328-A Substituted heteroaryl pyridopyrimidinone derivatives SANOFI AVENTIS (FR) 2009-10-21 — — CN claimed
WO-2008078196-A2 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 — — WO claimed
EP-1939187-A1 Substituted heteroaryl pyridopyrimidone derivatives Sanofi-Aventis (FR) 2008-07-02 — — EP claimed
CN-118344873-A Silicon nitride etching solution for inhibiting tip oxide regeneration, preparation method and application 浙江奥首材料科技有限公司 2024-07-16 — — CN disclosed
US-11236072-B2 N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-02-01 — — US disclosed
US-11236072-B2 N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-02-01 — — US disclosed
EP-3661928-B1 N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES BOEHRINGER INGELHEIM INT (DE) 2021-06-16 — — EP disclosed
EP-3661928-B1 N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES BOEHRINGER INGELHEIM INT (DE) 2021-06-16 — — EP disclosed
EP-3442965-B1 NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES BOEHRINGER INGELHEIM INT (DE) 2021-05-26 — — EP disclosed
US-20040014744-A1 Substituted pyridines having antiangiogenic activity ABBOTT LABORATORIES 2004-01-22 — — US disclosed
WO-2003086398-A1 AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2003-10-23 — — WO disclosed
CN-1353697-A 4-phenyl-pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2002-06-12 — — CN disclosed
EP-1187815-A1 4-PHENYL-PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-03-20 — — EP disclosed
US-6274588-B1 NEUROKININ OR SUBSTANCE P ANTAGONISTS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDES; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. 2001-08-14 — — US disclosed
WO-2000073279-A1 4-PHENYL-PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014744-A1 Substituted pyridines having antiangiogenic activity FLT1, FLT4, KDR NTRK1 1313/4885LDHA 2478/4885MEN1 2787/4885
US-11236072-B2 N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides HCRTR2, HCRTR1, CNR1 NTRK1 506/4885LDHA 2812/4885MEN1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.